Tytuł pozycji:
LBA54 - ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
-
Tytuł:
-
LBA54 - ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
-
Autorzy:
-
Motzer, R.J.
-
Źródło:
-
In Annals of Oncology October 2019 30 Supplement 5:v889-v890
-